A new study found the country has been at a life expectancy disadvantage since the 1950s, with more than 50 countries surpassing the U.S.
Author: Adrianna Rodriguez, USA TODAY
What is human metapneumovirus? What to know about the virus that flew under everyone’s radar.
Like many winter viruses, human metapneumovirus or hMPV is an infection that affects the upper and respiratory tract, according to the CDC.
A heart was flown from Alaska to Boston, breaking a transplant record. Here’s how it was done.
A heart traveled 2,506 miles, breaking the record for the furthest distance a human heart has ever traveled for a transplant.
Feinstein reveals shingles complications: What to know about encephalitis and Ramsay Hunt syndrome
Sen. Dianne Feinstein was diagnosed with encephalitis and Ramsay Hunt syndrome after having shingles. Here’s what to know.
A maternal RSV vaccine to protect infants is one step closer to FDA approval
The candidate vaccine created by Pfizer would be approved for pregnant people to help prevent severe disease in infants from birth through 6 months.
Students are increasingly refusing to go to school. It’s becoming a mental health crisis.
Since the pandemic, more students are school-avoidant, leaving parents feeling hopeless and schools unequipped to find a solution.
Drownings peak in the summer. What experts say about pool safety – and how to keep your child safe.
The tragic drowning of Tampa Bay Buccaneers player Shaquille Barrett’s daughter has prompted experts to issue warnings about pool safety.
What causes myocarditis in boys and young men after COVID vaccination? Study offers answers.
The risk of developing vaccine-related myocarditis is extremely low. A new study sheds light on what’s driving these cases of heart inflammation.
World Health Organization says COVID-19 is no longer a global emergency
The World Health Organization declared COVID-19 over as a global health emergency, a historic milestone after more than 7 million deaths worldwide.
FDA approves first-ever RSV vaccine, shots to be available for older adults
Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.